Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 1, 2006

Primary Completion Date

July 8, 2010

Study Completion Date

August 1, 2011

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Bortezomib

Trial Locations (15)

13273

Hopital Paoli Calmette, Marseille

14033

CHU de Caen, Caen

21000

CHU Dijon, Dijon

31059

CHU Purpan, Toulouse

33076

Institut Bergonie, Bordeaux

38043

CHU Albert Michallon, Grenoble

43033

CHU Angers, Angers

54511

CHU Brabois, Vandœuvre-lès-Nancy

66046

Centre Hospitalier Joffre, Perpignan

67098

Centre Hospitalier Universitaire de STRASBOURG, Strasbourg

75014

Hopital Cochin, Paris

76038

Centre Henry Becquerel, Rouen

87046

CHU de Limoges, Limoges

93009

Hopital Avicenne, Bobigny

06202

CHU Archet, Nice

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Johnson & Johnson

INDUSTRY

lead

Groupe Francophone des Myelodysplasies

OTHER